China NMPA Drug Inspection - Suzhou Chunhuitang Pharmaceutical Co., Ltd. - Fennel slices

The Shanghai Municipal Food and Drug Administration (SFDA) issued an announcement on April 9, 2018, detailing the results of its 2018 drug supervision and sampling inspections. These inspections targeted various drug and pharmaceutical packaging material manufacturers, distributors, and users, covering products from 2017 batches. Several companies were cited for non-compliance, including Suzhou Boyuan Pharmaceutical Co., Ltd., Shanghai Huayuan Pharmaceutical Co., Ltd., Shanghai First People's Hospital, Suzhou Chunhuitang Pharmaceutical Co., Ltd., and Shanghai Huayi Group Huayuan Chemical Co., Ltd. Main violations included "Content Determination" issues for Polygonum multiflorum and Fennel Seeds, indicating active ingredient levels did not meet standards. "Sulfur Dioxide Residue" exceeded limits in Glehnia littoralis, while "Content Difference" was noted in Clodisongol Cream, suggesting inconsistent active ingredient distribution. Additionally, "Moisture Absorption Rate" for solid pharmaceutical desiccant was found deficient. These findings were based on established regulatory frameworks, including the 2015 Edition of the Chinese Pharmacopoeia and Shanghai's specific processing regulations and quality standards. As a result, the SFDA mandated immediate risk control actions for the implicated companies. These actions included suspending sales and use, and recalling the substandard products. Furthermore, companies are required to investigate the root causes of non-compliance, develop and implement corrective action plans, and eliminate potential future risks. The SFDA also committed to intensified follow-up inspections and ongoing supervision to ensure compliance and market safety.